Eli Lilly and Company announced that John H. Johnson, senior vice president and president of Lilly Oncology, has resigned effective January 28, 2011. A successor will be announced in the coming weeks.
Health care giant Johnson & Johnson, hammered by numerous recalls that have kept some popular nonprescription medicines and other products off the market, posted a 12 percent profit decline and a 5.5 percent drop in revenue for the fourth quarter.
Hamilton Robotics has integrated Peak Robotics' KiNEDx robot series with Hamilton's MICROLAB STAR automated liquid handling workstation. The KiNEDx 4- and 5-axis robots increase the STAR's access to microplate samples and third-party devices.
Genetix announced the launch of its ClonePix 2 system – the second generation system based on the company’s well-established and successful technology and chemistries for clone screening and selection.
Despite what you might have heard, genetic sequencing alone is not enough to understand human disease. Researchers have shown that functional tests are absolutely necessary to understand the biological relevance of the results of sequencing studies.
HIV adapts in a surprising way to survive and thrive in its hiding spot within the human immune system, scientists have learned. While the finding helps explain why HIV remains, it also offers researchers a new, unexpected way to try to stop the virus.
PerkinElmer, Inc. announced the launch of a next generation DNA sequencing and data analysis services for genome sequencing at the company's lab in Branford, Conn.
Drug developer Teva Pharmaceutical Industries Ltd. said it signed a new three-year, $1.5 billion credit facility. The company said the new facility is part of its strategy to secure liquidity for future business needs through revolving credit lines.
Pharmasset Inc. said it is publicly offering just under $106.6 million in common stock, with an additional $46.3 million being offered by shareholders.
Bayer HealthCare Pharmaceuticals Inc. said that a Food and Drug Administration advisory panel has recommended approval of its injectable imaging agent for use in MRI scans.
Biotechnology company Clinical Data Inc. said the Food and Drug Administration approved the major depressive disorder treatment Viibryd. The company said the drug should be available in U.S. pharmacies in the second quarter.
Rexahn Pharmaceuticals Inc. said that Teva Pharmaceutical Industries Ltd. bought $3.95 million of the company's stock in a private offering. The investment gives Teva a 6.29 percent ownership stake in Rexahn.
Lupus drug developer Human Genome Sciences Inc. said it appointed former Wyeth Chief Financial Officer Greg Norden to its board of directors.
The Food and Drug Administration has asked Vivus Inc. to study the rate of side effects associated with one of the ingredients of its obesity drug candidate, Qnexa.
A regulatory committee recommended that a seizure drug developed by GlaxoSmithKline and Valeant Pharmaceuticals be approved in the European Union, the companies said.